Abstract
Purpose:
We reviewed the pertinent literature and discuss high throughput approaches to the identification of molecular markers characteristic of prostate cancer.
Materials and Methods:
A PubMed search was performed for expression array studies comparing prostate cancer tissues with nonmalignant tissues and serum proteomic studies comparing patients with prostate cancer and controls.
Results:
The expression of several genes may help distinguish prostate cancer cells from nonmalignant prostatic epithelial cells. A few genes, such as those coding for hepsin, LIM protein and α-methylacyl-coenzyme A racemase, have consistently been identified as being over expressed in cancer cells compared with nonmalignant cells. Proteomic analysis using mass spectroscopy has identified spectral patterns that have a significant correlation with the presence of prostate cancer. The optimal presentation of the spectra may depend highly on technical factors and experimental protocols have yet to be standardized among laboratories. Moreover, to our knowledge the serum proteins that comprise the mass spectral patterns of prostate cancer have yet to be identified.
Conclusions:
High throughput techniques have the potential to aid in prostate cancer diagnosis, early detection and developmental therapies. Markers with the potential to aid in diagnosis have been identified and targets for imaging or therapeutic approaches appear to be at hand. Mass spectral analysis of serum is in the early stages and it requires standardization of technical parameters among laboratories. In addition, the identification of target proteins will contribute to ease of detection and cross-laboratory verification.
References
- 1 : Identification of differentially expressed genes in normal and malignant prostate by electronic profiling of expressed sequence tags. Cancer Res2002; 62: 3308. Google Scholar
- 2 : Identification of differentially expressed genes by serial analysis of gene expression in human prostate cancer. Cancer Res2001; 61: 4283. Google Scholar
- 3 : Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res2000; 60: 1677. Google Scholar
- 4 : Alpha-methylacyl coenzyme A racemase as a marker for prostate cancer. JAMA2002; 287: 3080. Google Scholar
- 5 : Alpha-methylacyl-CoA racemase: a variably sensitive immunohistochemical marker for the diagnosis of small prostate cancer foci on needle biopsy. Am J Surg Pathol2003; 27: 1128. Google Scholar
- 6 : Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res2001; 61: 4683. Google Scholar
- 7 : Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res2001; 61: 5974. Google Scholar
- 8 : Delineation of prognostic biomarkers in prostate cancer. Nature2001; 412: 822. Google Scholar
- 9 : Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res2001; 61: 5692. Google Scholar
- 10 : Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res2002; 62: 4427. Google Scholar
- 11 : Characterization of the androgen-regulated prostate-specific T cell receptor gamma-chain alternate reading frame protein (TARP) promoter. Endocrinology2003; 144: 3433. Google Scholar
- 12 : T-cell receptor gamma chain alternate reading frame protein (TARP) expression in prostate cancer cells leads to an increased growth rate and induction of caveolins and amphiregulin. Cancer Res2001; 61: 8122. Google Scholar
- 13 : Tumor progression is accompanied by significant changes in the levels of expression of polyamine metabolism regulatory genes and clusterin (sulfated glycoprotein 2) in human prostate cancer specimens. Cancer Res2000; 60: 28. Google Scholar
- 14 : Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res2002; 62: 3609. Google Scholar
- 15 : Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst2002; 94: 1576. Google Scholar
- 16 : Early detection research program at the NCI. Int J Cancer1996; 69: 35. Google Scholar
- 17 : The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials2001; 21: 249S. Google Scholar
- 18 : Expression and diagnostic utility of alpha-methylacyl-CoA-racemase (P504S) in foamy gland and pseudohyperplastic prostate cancer. Am J Surg Pathol2003; 27: 772. Google Scholar
- 19 : Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays. Cancer Res2002; 62: 1256. Google Scholar
- 20 : Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice. Cancer Res2000; 60: 5125. Google Scholar
- 21 : Alpha-difluoromethylornithine and polyamine levels in the human prostate: results of a phase IIa trial. J Natl Cancer Inst2001; 93: 57. Google Scholar
- 22 : Low-dose difluoromethylornithine and polyamine levels in human prostate tissue. J Natl Cancer Inst1999; 91: 1416. Google Scholar
From the Department of Oncology, Lombardi Cancer Center, Georgetown University, Washington, D. C., and Virginia Prostate Center, Department of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, Norfolk, Virginia
